President Trump announced imported generics will enter the US tariff-free from 1 August 2026 to 31 July 2028, then face 100% tariffs for one year and 200% permanently thereafter, forcing manufacturers to build domestic production capacity during the grace period.
President Donald Trump announced on 21 July 2026 that generic drugs imported into the United States will enjoy a zero-tariff window through 31 July 2028, after which tariffs will accelerate sharply. Once the grace period ends, imported generics will face 100% tariffs for twelve months, jumping to 200% permanently thereafter.
“Effective August 1st, 2026, all Generic Drugs being brought into the United States will continue to have a TARIFF of ZERO PERCENT for a two year period of time, after which the TARIFF will be raised to 100% for a one year period of time, and 200% thereafter. This is done in order to RESHORE Generic Pharmaceutical Production into America, with a penalty to those Companies that decide not to build Plant and Equipment within the stated period of time given to them”, Trump posted on Truth Social.
The stated aim is straightforward: force pharmaceutical manufacturers to build domestic production capacity rather than rely on foreign supply chains. Companies that fail to invest in US plants during the two-year window will absorb the penalty through escalating duties.
The policy targets a critical choke point in American healthcare. The FDA confirms that over 90% of medicines sold domestically are generic formulations, meaning the tariff regime could significantly affect drug prices and supply stability within two years.
Branded and patented drugs are exempt from this announcement, though Trump’s April executive order already imposed 100% tariffs on certain innovative drugs unless manufacturers agree to government pricing deals or commit to domestic production.
This move stacks on Trump’s existing most-favoured-nation drug pricing strategy, which pressures manufacturers to match prices paid by patients in other wealthy countries. Major drugmakers including Eli Lilly and Pfizer secured tariff exemptions worth billions last year, but the new timeline reshapes the calculus for generic manufacturers specifically.
